

# CIHR–PHSI: Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) NEWSLETTER

*Developing a Framework for the Incorporation of Real World Evidence (RWE) into Cancer Drug Funding Decisions in Canada*

Issue 3 – Spring 2018

## WELCOME & THANK YOU

Welcome to the latest edition of the CIHR-PHSI CanREValue project newsletter!

Thank you for attending the in-person meeting on May 29<sup>th</sup>, 2018 in Montreal. This edition of our newsletter will summarize some of the discussions that took place that day, and keep you updated about current work including next steps.

## OBJECTIVE 1:

### QUALITATIVE STUDY: (LED BY YVONNE BOMBARD AND TEAM)

**Objective:** Overview of stakeholders' perspectives towards the development, and implementation of a framework for incorporation and use of RWE.

**Method:** 30 semi-structured in-person/phone interviews

**Preliminary results – Major themes:** (n = 13)

1. **Enthusiasm in using RWE** – focused around “value for money”
2. **Current state of data readiness**
  - General awareness and understanding of existing data challenges and the need for high quality data; but how should current infrastructure be transformed to output the quality of data for RWE?
3. **Limited resources and capacity**
  - Lack of experts to undertake RWE research and questions around funding availability for RWE
4. **Increase collaboration among key stakeholders**

**Next Steps:** Continue to sample stakeholders, emphasizing on stakeholders from industry, patient groups, and international organizations.

## Study Objectives:

### Objective 1: (ongoing)

- ❖ Develop comprehensive understanding of the current state of RWE nationally & internationally

### Objective 2: (ongoing)

- ❖ Establish formal national working groups dedicated to policy and methodological application of RWE, and collaboratively & iteratively develop a working framework

### Objective 3: (upcoming)

- ❖ Validate the developed framework through the completion of multi-province RWE project

### Objective 4: (upcoming)

- ❖ Employ knowledge translation strategies to establish and integrate the final RWE framework provincially

## ENVIRONMENTAL SCAN: (CANCER CARE ONTARIO'S EVIDENCE SEARCH AND REVIEW SERVICE)

**Objective:** To understand current state of RWE in healthcare decision making nationally and internationally

**Method:** Scoping review supplemented by environmental scan

### Summary Results:

1. **Definitions of RWE & RWD:** Absence of a universal pragmatic definition for RWD. RWE is often defined as analysis & interpretation of RWD.
2. **Collection of RWD for the generation of RWE:** Often conceptualized through the source of data (e.g. registries & databases) or study design (e.g. pragmatic trials & observational studies).
3. **Role of RWE:**
  - For decision-makers & payers, RWE can be used for both pre-market & post-market evaluations.
  - For HTA, RWE can support initial reimbursement decisions and conditional reimbursement schemes. Facilitators of RWE use includes improving data access, resources, and collaborations across stakeholders, and consensus on definitions and standards.

**Next Steps:** Knowledge translation through the publication of a manuscript on the results.

## OBJECTIVE 2:

### UPDATES FROM WORKING GROUPS:

	Planning and Drug Selection	Data	Methods	Reassessment and Uptake
<b>Chair</b>	Scott Gavura	Claire De Oliveira	Jeff Hoch	Alex Chambers
<b>Mandate</b>	To develop the criteria to identify potential drug candidates for real world evaluation and establish provincial infrastructure for RWE	To identify strategies for data access across provinces and harmonize data elements relevant for RWE studies.	To recommend methods to analyze real world data with methodological rigor	To develop strategies for implementing RWE and results for HTA reassessment and policy decisions
<b>Progress to date</b>	Two teleconferences Members completed two surveys One in-person meeting	One teleconference Members completed a worksheet on data elements and databases One in-person meeting	One teleconference Members reviewed a list of existing methods in current literature One in-person meeting	Two teleconferences Members completed two surveys One in-person meeting
<b>Next Steps</b>	Teleconferences/emails/survey to discuss additional policy issues arising Draft report/manuscript on current findings Apply framework to identify drugs and questions to initiate Objective 3	Teleconferences/emails/surveys to finalize data elements in each province Draft report/manuscript on current findings Collaborate with policy and data working groups to identify feasible drug candidate to initiate Objective 3	Teleconferences/emails/surveys to discuss outstanding issues arising Draft report/manuscript on current findings Apply framework to identify methods to answer chosen questions in Objective 3	Teleconference/email/survey to discuss additional policy issues arising Draft report/manuscript on current findings Apply framework to identify reassessment and uptake process in Objective 3

### ESTABLISHING THE ENGAGEMENT WORKING GROUP

- ❖ Mandate: To develop strategies for the engagement of various stakeholders for the refinement and use of RWE framework.
- ❖ Next step: Identify chair and working group members

### IN-PERSON MEETING:

- ❖ On May 29<sup>th</sup>, 2018, the first in-person meeting for the project was hosted in Montreal. A great number of working group members and grant collaborators attended in-person or via teleconference.
- ❖ The morning began with a working session where each working group tackled specific issues and concerns. Following the working session, attendees convened for presentations from the qualitative team and the chairs of each working group. Lastly, attendees separated into small groups to discuss questions around RWE framework and presented their discussions to the overall group.

### NEXT STEPS

- ❖ With collaboration from all working group members, we will initiate objective 3.
- ❖ A detailed summary from the in-person meeting will be circulated.

For questions and information, please contact Wei Fang Dai at [WeiFang.Dai@cancercare.on.ca](mailto:WeiFang.Dai@cancercare.on.ca).